Skip to content
Clinical Trials – home

Find therapies in clinical trials near you

recruiting
3 979
countries
28
conditions
2 106

10 trials match your criteria

Comparison of dapagliflozin and oral semaglutide effectiveness in type 2 diabetes patients based on insulin resistance or secretion deficit

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin

Type 2 diabetes mellitus

Not yet recruiting

Study of zenagamtide versus insulin glargine in adults with type 2 diabetes and high cardiovascular risk uncontrolled on oral medications

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years
  • Substances:Insulin Glargine

Type 2 diabetes mellitus

Not yet recruiting

Comparison of weekly insulin icodec versus daily basal insulin in adults with type 2 diabetes who have not used insulin before

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Insulin degludec

Study on the Effectiveness of Weekly IcoSema (Insulin Icodec and Semaglutide) vs. Daily Insulin Glargine for Adults with Type 2 Diabetes Not Controlled by Oral Drugs

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin

Study on Insulin Glargine for Patients with Type 2 Diabetes: Comparing Decentralized, Hybrid, and Standard Clinical Trial Approaches

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Insulin Glargine

A study testing cagrilintide and semaglutide compared to placebo in people with type 2 diabetes taking basal insulin with or without metformin

Registered drug
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide

Comparing weekly insulin icodec and daily insulin glargine with insulin aspart in adults with type 1 diabetes: a 26-week study of blood sugar control

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Insulin Glargine

Study on the Effects of Ertugliflozin and Semaglutide on Heart Health in Patients with Type 2 Diabetes

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Canagliflozin

Type 2 diabetes mellitus+1

Not recruiting

Study comparing semaglutide with insulin glargine in overweight adults with type 2 diabetes: effectiveness of combined treatment versus insulin alone

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Insulin Glargine

Type 2 diabetes mellitus+3

Not recruiting

Evaluating Once Daily Orforglipron (LY3502970) Compared to Insulin Glargine in Adults with Type 2 Diabetes and Obesity or Overweight who Have Increased Cardiovascular Risk

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Canagliflozin
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.